GOAL OF WORK: The admission of patients with hematological disorders to the intensive care unit (ICU) involves a complex resource usage and may be associated with high mortality. The decision making to transfer a severely ill patient to the ICU, therefore, presents an ethical dilemma. We assessed both early and long-term outcomes in relation to clinical characteristics with the aim to facilitate clinical decision making. MATERIALS AND METHODS: We performed a cohort study of hematological patients admitted to ICU at a university hospital. MAIN RESULTS: During a 6-year period (1996-2001), 85 patients with a median age of 59 years were admitted to ICU. The majority of patients (88%) suffered from hematological malignancies. Major reasons for ICU admission were respiratory failure (41%) and septic shock/pre-shock (24%). The median duration of ICU admission was 2 (1-67) days. Crude in-ICU, 30-day, and 6-month mortality rates were 30, 49, and 62%, respectively. Overall 5-year survival rate was 20%, and 13 (15%) patients were alive at time of follow-up (median 7.4 years). Respiratory failure requiring ventilatory support and a high Acute Physiology and Chronic Health Evaluation II score was significantly correlated to high in-ICU mortality, but not to long-term outcome. Type of hematological malignancy, neutropenia, thrombocytopenia, bacteremia, prior administration of chemotherapy, age, or gender was not significantly associated with outcome. CONCLUSIONS: The current study provides encouraging results on long-term post-ICU outcome also in elderly patients with hematological diseases. For a substantial proportion of critically ill hematological patients, a short time care at an ICU is lifesaving. These patients should be offered intensive care unless or until it is clear that there is little prospect of recovery from the acute illness or that the underlying malignancy cannot be controlled.
GOAL OF WORK: The admission of patients with hematological disorders to the intensive care unit (ICU) involves a complex resource usage and may be associated with high mortality. The decision making to transfer a severely ill patient to the ICU, therefore, presents an ethical dilemma. We assessed both early and long-term outcomes in relation to clinical characteristics with the aim to facilitate clinical decision making. MATERIALS AND METHODS: We performed a cohort study of hematological patients admitted to ICU at a university hospital. MAIN RESULTS: During a 6-year period (1996-2001), 85 patients with a median age of 59 years were admitted to ICU. The majority of patients (88%) suffered from hematological malignancies. Major reasons for ICU admission were respiratory failure (41%) and septic shock/pre-shock (24%). The median duration of ICU admission was 2 (1-67) days. Crude in-ICU, 30-day, and 6-month mortality rates were 30, 49, and 62%, respectively. Overall 5-year survival rate was 20%, and 13 (15%) patients were alive at time of follow-up (median 7.4 years). Respiratory failure requiring ventilatory support and a high Acute Physiology and Chronic Health Evaluation II score was significantly correlated to high in-ICU mortality, but not to long-term outcome. Type of hematological malignancy, neutropenia, thrombocytopenia, bacteremia, prior administration of chemotherapy, age, or gender was not significantly associated with outcome. CONCLUSIONS: The current study provides encouraging results on long-term post-ICU outcome also in elderly patients with hematological diseases. For a substantial proportion of critically ill hematologicalpatients, a short time care at an ICU is lifesaving. These patients should be offered intensive care unless or until it is clear that there is little prospect of recovery from the acute illness or that the underlying malignancy cannot be controlled.
Authors: J Evison; P Rickenbacher; R Ritz; A Gratwohl; C Haberthür; S Elsasser; J R Passweg Journal: Swiss Med Wkly Date: 2001-12-22 Impact factor: 2.193
Authors: Dominique D Benoit; Koenraad H Vandewoude; Johan M Decruyenaere; Eric A Hoste; Francis A Colardyn Journal: Crit Care Med Date: 2003-01 Impact factor: 7.598
Authors: Fabrice Thiolliere; Anne Françoise Serre-Sapin; Jean Reignier; Marcel Benedit; Jean Michel Constantin; Christine Lebert; Dominique Guélon; Jean François Timsit; Bertrand Souweine Journal: Intensive Care Med Date: 2013-06-06 Impact factor: 17.440
Authors: Suhail S Siddiqui; Natesh R Prabu; Harish K Chaudhari; Amit M Narkhede; Satish V Sarode; Ujwal Dhundi; Jigeeshu V Divatia; Atul P Kulkarni Journal: Indian J Crit Care Med Date: 2021-01
Authors: William M Townsend; Ailsa Holroyd; Rachel Pearce; Stephen Mackinnon; Prakesh Naik; Anthony H Goldstone; David C Linch; Karl S Peggs; Kirsty J Thomson; Mervyn Singer; David C J Howell; Emma C Morris Journal: Br J Haematol Date: 2013-03-18 Impact factor: 6.998
Authors: G Maschmeyer; J Carratalà; D Buchheidt; A Hamprecht; C P Heussel; C Kahl; J Lorenz; S Neumann; C Rieger; M Ruhnke; H Salwender; M Schmidt-Hieber; E Azoulay Journal: Ann Oncol Date: 2014-05-15 Impact factor: 32.976